Friday, July 17, 2026
🇺🇸 FDA

QA/QC Tools · CAPA · GMP · ICH Q10

CAPA Template — Corrective & Preventive Action

Interactive pharmaceutical CAPA form covering identification, root cause analysis, impact assessment, actions, and effectiveness check. MasterControl and SimplerQMS offer enterprise or downloadable forms; this free tool adds dynamic action rows and CAPA number generation.

Quick Answer

CAPA (Corrective Action and Preventive Action) is a pharmaceutical quality system process to investigate root causes of quality failures, implement corrections, and prevent recurrence. This interactive template covers identification, problem description, root cause analysis, impact assessment, corrective and preventive actions, effectiveness check, and QA approval. Required under ICH Q10, EU GMP Chapter 1, and FDA quality system expectations. Print or save as PDF—integrate with your validated eQMS for regulatory submissions.

Section 1 — CAPA Identification
Section 2 — Problem Description
Section 3 — Root Cause Analysis
Section 4 — Impact Assessment
Section 5 — Corrective Actions

Actions to correct the identified problem (reactive). Address the root cause directly.

Section 6 — Preventive Actions

Actions to prevent recurrence (proactive). May include SOP updates, training, system changes, or controls.

Section 7 — Effectiveness Check
Section 8 — Approval

How to Use This Template

1
Generate a CAPA number and complete Section 1 identification—source, reference, priority, department.
2
Write a factual problem statement with containment actions taken immediately after discovery.
3
Conduct root cause analysis, document evidence, and score impact on patient safety, product quality, and regulatory compliance.
4
Add corrective and preventive action rows with owners, due dates, and status. Extend rows as needed.
5
Define effectiveness criteria, obtain QA approval, and print/save PDF for the quality management system.

Pharma / GMP Context for QA Professionals

CAPA is the closure mechanism for quality events across the pharmaceutical lifecycle. ICH Q10 integrates CAPA with change control, management review, and knowledge management—regulators expect CAPA records to demonstrate that root causes were verified, not guessed, and that effectiveness was objectively measured after implementation.

FDA inspectors frequently cite overdue CAPAs, weak root cause statements ("operator error" without systemic analysis), and missing effectiveness checks. EU GMP and WHO inspections apply similar scrutiny. Link each CAPA to its triggering event via reference numbers and ensure impact assessment addresses other potentially affected batches.

Source events from the Deviation Report Template, OOS Investigation Template, and GMP Checklist Generator audit findings. Prioritize failure modes with the RPN Calculator before they escalate to CAPA.

Evidence and Sources

Frequently Asked Questions

Corrective Action and Preventive Action (CAPA) is a systematic process used in pharmaceutical quality management to identify the root cause of quality failures, implement corrections, and prevent recurrence. CAPA systems are required under 21 CFR 820 (medical devices), ISO 13485, EU GMP Chapter 1, and ICH Q10 Pharmaceutical Quality System.
Corrective action addresses an existing, confirmed problem—it is reactive, responding to something that has already occurred. Preventive action addresses potential problems identified proactively through risk assessment, trend analysis, or audit findings, before a failure actually occurs. Both require root cause analysis and verification of effectiveness.
Industry standard expectations: Critical and High priority CAPAs should be closed within 30 days; Medium priority within 60 days; Low priority within 90 days. Timeframes should be defined in the organization quality SOP. CAPAs that cannot meet target dates require approved extensions with documented justification. Overdue CAPAs are a common FDA inspection observation.
CAPAs are typically triggered by deviations, OOS/OOT results, internal or external audit findings, customer complaints, product recalls, regulatory observations (Form 483, Warning Letter), risk assessment outputs, adverse trend analysis, or change control review requiring systemic correction.
Common methods include 5-Why analysis, Fishbone (Ishikawa) diagrams, Fault Tree Analysis (FTA), and FMEA. ICH Q9(R1) does not mandate a specific technique but expects scientifically sound investigation proportionate to risk. Document the method selected, evidence reviewed, and why the stated root cause is verified—not assumed.
Effectiveness verification confirms that implemented corrective and preventive actions actually resolved the root cause and prevented recurrence. Define measurable criteria upfront—for example zero repeat deviations in six months, passing re-audit, or improved process capability. Ineffective CAPAs must be reopened with additional actions; partially effective CAPAs require escalation.
A deviation documents a specific departure from an approved procedure or specification at a point in time. A CAPA is the systemic response that may span multiple deviations, audit findings, or risk assessments. One deviation may trigger one CAPA; recurring minor deviations often consolidate into a single CAPA addressing the underlying root cause.
While 21 CFR Part 211 does not use the acronym CAPA, FDA expects manufacturers to investigate unexplained discrepancies (§211.192), implement corrections, and prevent recurrence through the pharmaceutical quality system per ICH Q10. Medical device manufacturers face explicit CAPA requirements under 21 CFR 820.100. FDA inspection observations frequently cite inadequate CAPA systems.
A strong problem statement is factual and specific: who discovered the issue, what happened, where (department, equipment, batch), when (date/time), and how much material or how many units were affected. Avoid blame language. Link to source records—deviation number, OOS number, audit observation ID, or complaint reference—for traceability.
Recall or field corrective action is required when impact assessment confirms patient safety risk, distributed batches may not meet specification, or regulatory notification thresholds are met (FDA 21 CFR Part 7, EU FSCA). Document the recall decision, affected batch traceability, and regulatory notifications in the CAPA impact assessment section.
This template supports drafting, training, and small-site documentation. Commercial manufacturers under 21 CFR Part 11 typically require validated electronic QMS platforms (MasterControl, Veeva, etc.) with audit trails, electronic signatures, and access controls. Use this form for mock audits, gap analysis, or CAPA planning—not as a replacement for validated systems in GMP production environments.
CAPA connects to the Deviation Report Template (event source), OOS Investigation Template (laboratory failures), GMP Checklist Generator (audit findings), RPN Calculator (FMEA risk input under ICH Q9), and Stability Schedule Generator (stability program gaps). Close the loop with effectiveness metrics in management review.

Related Tools

☰RPN Calculator 📅Stability Schedule ✅GMP Checklist 🏭Cleanroom Classification

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.